Medindia

X

Reportlinker Adds China Pharmaceutical Regulatory Report 2010 + Appendix

Wednesday, February 17, 2010 General News J E 4
Advertisement


NEW YORK, Feb. 16 Reportlinker.com announces that a new market research report is available in its catalogue:

China Pharmaceutical Regulatory Report 2010 + Appendix

http://www.reportlinker.com/p0177882/China-Pharmaceutical-Regulatory-Report-2010-+-Appendix.html

This report includes a brief overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutical products. Specific topics include: product registration, pricing and reimbursement, importation, GMP, GCP, orphan drugs, and intellectual property protection. This report's appendix contains a full translation of the revised Administrative Provisions for Drug Registration, the recent overhaul of China's drug regulations. It also contains the annexes to this document detailing dossier submission requirements, all up-to-date. Fully updated for 2010! Completely new information has been added to this report, including distribution in Section I, the 2009 Health Care Reform in Section II, new regulatory changes in Section III, drug purchasing system in Section VII, and drug safety in Section VIII. There are also updates on drug registration statistics, GMP, re-registration processes, and packing requirements. The appendix has also been updated, such as CRO information and SFDA affiliate organizations.

I. China Pharmaceutical Industry Overview

A. Overview

B. China Pharmaceutical Market Trends

C. China's Pharmaceutical Distribution System

D. Brief Overview of China's Pharmaceutical Regulations

E. The State Food and Drug Administration

II. The China Healthcare System

A. History of Healthcare System in China

B. Struggling Healthcare Services Sector

C. Hospitals and Medical Resources

D. Health Insurance in China

E. 2009 Health Care Reform

III. Drug Registration Regulations

A. Drug Registration Policy

B. Classification of Drugs

C. Drug Registration Application

D. Application Documents for New Drug Registration

E. Technical Review Guidance for Registration Documents

F. New Drug Registration Process

G. OTC New Drug Registration Process

H. New Drug Registration Statistics

I. Classification of Combination Drug-Device Products

J. New Regulatory Changes

IV. Drug Pricing Regulations

A. Overview of Drug Pricing

B. Controls on Drug Pricing

C. National Essential Medical Insurance Drug List V. Pharmaceutical Research and Development and Related Regulations

A. China's Research and Development Climate

B. Clinical Research

C. Good Clinical Practice (GCP)

D. GCP-Certified Clinical Research Centers

E. Good Laboratory Practice (GLP)

F. Adverse Event Reporting Requirements

VI. Pharmaceutical Manufacturing Regulations

A. Manufacturing Pharmaceuticals in China

B. GMP Regulations

C. GMP Certification

D. Drug Manufacturing Administration

E. Drug Manufacturing Certificate

F. Biological Products

VII. Selling Pharmaceuticals and Related Regulations

A. WTO Agreement on Drug Sales

B. Drug Sales to Hospitals

C. Drug Purchasing System

D. Selling Drugs in Drug Stores

E. Drug Sales on the Internet

F. Distribution Regulations

G. OTC Drug Sales

H. Regulations on Drug Imports

I. Drug Recalls

VIII. Drug Safety

IX. Authorized Quality Person

X. Marketing Drugs in China

A. Packaging Requirements

XI. Drug Advertising

XII. Intellectual Property Protection

A. Current Intellectual Property Situation in China Pharmaceutical Market

B. Examples of Pharmaceutical Companies Experience with IPR infringement in China

C. Administration Protection (AP)

XIII. Conclusion APPENDICES:

A. Application Form for Drug Registration

B. Listing of CROs in China; Regulatory Specifics for Clinical Trials in China

C. Administrative Provisions for Drug Registration (translated law)

D. Registration for TCM (translated law)

E. Registration for Chemical Drugs (translated law)

F. Registration for Biological Drugs (translated law)

G. Supplemental Drug Application Registration (translated law)

H. Drug Re-registration Application (translated law)

I. Drug Monitoring Periods

J. Application and Approval Procedures and Timeline for Imported Drugs

K. Application and Approval Procedures and Timeline for Clinical Trials

L. Listing of SFDA-affiliated organizations in China

M. Healthcare statistics in Asia (charts)

To order this report:

Pharmaceutical Industry: China Pharmaceutical Regulatory Report 2010 + Appendix

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Thomson Reuters and Ingenious Med Improve Inpatien...
S
Covidien Announces New Source of Vital Medical Iso...